Pablo Caballero-María
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Pablo Caballero-María has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Díaz-Cáceres
Lipids and Atherosclerosis Unit, Maimonides Institute for Biomedical Research in Cordoba (IMIBIC), University of Cordoba, Reina Sofia University Hospital, Cordoba, Spain. CIBER Physiopathology of Obesity and Nutrition (CIBEROBN), Institute of Health Carlo
1 shared publication - Antonio Camargo
Lipids and Atherosclerosis Unit, Department of Internal Medicine, Reina Sofia University Hospital, 14004 Córdoba, Spain
1 shared publication - Fernando Rodríguez-Cantalejo
Maimonides Biomedical Research Institute of Cordoba (IMIBIC), 14004 Córdoba, Spain
1 shared publication - Javier Arenas-Montes
Reina Sofia University Hospital
1 shared publication - Javier Caballero-Villarraso
Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), 14004 Córdoba, Spain
1 shared publication - Javier Delgado-Lista
Unidad de Lípidos y Arteriosclerosis, Servicio de Medicina Interna, Hospital Universitario Reina Sofía, IMIBIC, Córdoba, España. Departamento de Ciencias Médicas y Quirúrgicas, Universidad de Córdoba, Córdoba, España. CIBER fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, España; Grupo de trabajo de Nutrición y Estilo de Vida, Sociedad Española de Arteriosclerosis, España
1 shared publication
Latest Publications
- Open Access
- 19 February 2025
- Published by MDPI AG in Applied Sciences
- Vol. 15 (4) , 2228
Deep Learning Model Approach to Predict Diabetes Type 2 Based on Clinical, Biochemical, and Gut Microbiota Profiles
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease. Gut microbiota plays a key role in metabolic homeostasis and the development of T2DM and its complications. With the advance of artificial intelligence (AI), it is possible to develop novel models based on machine learning (ML) that can predict the risk of developing certain diseases and facilitate their early diagnosis, or even take preventive measures in advance. This can be the case of T2DM, for example. Our objective was to develop a predictive model of the risk of developing T2DM based on clinical, biochemical, and intestinal microbiota parameters, which estimates the time margin for developing this disease. To this end, a Deep Learning Multilayer Perceptron (MLP) algorithm was developed and trained with data from real patients from a current large population epidemiological study. The data were normalised and augmented to increase their diversity and avoid overfitting. The neural network developed was optimised, and the best hyperparameters were chosen for model building by Bayesian optimisation. We succeeded in getting the model to return a numerical result corresponding to the number of months it will take for a particular individual to develop T2DM with an accuracy of 95.2%.
- 19 February 2025
- Published by MDPI AG in Applied Sciences
- Vol. 15 (4) , 2228
Open AccessDeep Learning Model Approach to Predict Diabetes Type 2 Based on Clinical, Biochemical, and Gut Microbiota Profiles
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease. Gut microbiota plays a key role in metabolic homeostasis and the development of T2DM and its complications. With the advance of artificial intelligence (AI), it is possible to develop novel models based on machine learning (ML) that can predict the risk of developing certain diseases and facilitate their early diagnosis, or even take preventive measures in advance. This can be the case of T2DM, for example. Our objective was to develop a predictive model of the risk of developing T2DM based on clinical, biochemical, and intestinal microbiota parameters, which estimates the time margin for developing this disease. To this end, a Deep Learning Multilayer Perceptron (MLP) algorithm was developed and trained with data from real patients from a current large population epidemiological study. The data were normalised and augmented to increase their diversity and avoid overfitting. The neural network developed was optimised, and the best hyperparameters were chosen for model building by Bayesian optimisation. We succeeded in getting the model to return a numerical result corresponding to the number of months it will take for a particular individual to develop T2DM with an accuracy of 95.2%.